ABCB1 and ABCC1 variants associated with virological failure of first]line protease inhibitors antiretroviral regimens in northeast Brazil patients

Journal of Clinical Pharmacology

Volumn 53, Issue 12, 2013, Pages 1286-1293

  Coelho, Antonio V C ^a   Silva, Suedja P S ^a   De Alencar, Luiz C A ^b   Stocco, Gabriele ^c   Crovella, Sergio ^a   Brandão, Lucas A C ^a   Guimarães, Rafael L ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b Fernando Figueira Institute of Integrated Medicine   (Brazil)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

HIV 1; Pharmacodynamics; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; ORGANIC ANION TRANSPORTER D; ORGANIC CATION TRANSPORTER 1;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BRAZIL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENETIC ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

HIV-1; PHARMACODYNAMICS; PHARMACOGENETICS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84893014838     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.165     Document Type: Article

References (39)

1. De Cock KM, Jaffe HW, Curran JW. Reflections on 30 years of AIDS. Emerg Infect Dis. 2011;17(6):1044-1048.
2. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Genebra: UNAIDS; 2010.
3. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. 2009;85 (1):190-200.
4. Princeton DC. 2003. Manual of HIV/AIDS therapy. Laguna Hills, California: Current Clinical Strategies Publishing.
5. Telenti A, Zanger UM. Pharmacogenetics of antiHIV drugs. Annu Rev Pharmacol Toxicol. 2008;48:227-256.
6. Giraud C, Manceau S, Treluyer JM. ABC transporters in human lymphocytes: Expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opin Drug Metab Toxicol. 2010;6(5):571-589.
7. Wang H, Tompkins LM. CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9 (7):598-610.
8. Jung N, Lehmann C, Rubbert A, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008;36 (8):1616-1623.
9. Janneh O, Anwar T, Jungbauer C, et al. Pglycoprotein, multidrug resistanceassociated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther. 2009;14(7):965-974.
10. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV1infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet. 2002;359(9300):30- 36.
11. Alves S,D'avila S, de Freitas MA, et al. 2012. Progress report on the brazilian response to HIV/AIDS. Brasil: Departamento de DSTAIDS e Hepatites Virais.
12. SuarezKurtz G. Pharmacogenomics in admixed populations: The Brazilian pharmacogenetics/pharmacogenomics network - REFARGEN. Pharmacogenomics J. 2004;4(6):347-348.
13. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV1infected adults and adolescents. 2012.
14. Brumme ZL, DongWW,Chan KJ, et al. Influence of polymorphisms within the CX3CR1 and MDR1 genes on initial antiretroviral therapy response. AIDS. 2003;17(2):201-208.
15. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1infected individuals with cytochrome P450 2B6 -6 and -26. Clin Infect Dis. 2007;45(9):1230-1237.
16. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis. 2009;199 (6):872-880.
17. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIVinfected patients: An update. Infect Genet Evol. 2007;7(2):333-342.
18. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study. J Infect Dis. 2010;202(5):717-722.
19. Minuesa G, Volk C, MolinaArcas M, et al. Transport of Lamivudine [(-)bl20,30 Dideoxy30 thiacytidine] and highaffinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2 and J Pharmacol Exp Ther. 2009;329 (1):252-261.
20. Shen LX, Basilion JP, Stanton VP, Jr. Singlenucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci USA. 1999;96(14):7871-7876.
21. The HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-796.
22. Hochman JH, Chiba M, Yamazaki M, Tang C, Lin JH. Pglycoprotein mediated efflux of indinavir metabolites in Caco2 cells expressing cytochrome P450 3A4. J Pharmacol Exp Ther. 2001;298(1):323-330.
23. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65-70.
24. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd edition. New York: Wiley; 2000.
25. R Development Core Team. R: A language and environment for statistical computing. Available at: Http://www.rproject.org/. Accessed June 18, 2010.
26. Hutchinson JF. The biology and evolution of HIV. Ann Rev Anthropol. 2001;30: (ArticleType: Researcharticle/Full publication date: 2001/Copyright © 2001 Annual Reviews): 85-108.
27. World Health Organization. 2007. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIVrelated disease in adults and children. Geneva: World Health Organization.
28. Ministério da Saúde. 2012. Boletim Epidemiológico - Aids e DST. Brasília, DF: Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais. Ano VIII, n° 1.
29. Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection. Pharmacol Res. 2008;58(3-4):173- 182.
30. Manrique L, Aziz M, Adeyemi OM. Successful immunologic and virologic outcomes in elderly HIVinfected patients. J Acquir Immune Defic Syndr. 2010;54(3):332-333. 310.1097/QAI.1090b1013e3181d1092eef1091.
31. Paintsil E, Dutschman GE, Hu R, et al. Determinants of individual variation in intracellular accumulation of antiHIV nucleoside analog metabolites. Antimicrob Agents Chemother. 2011;55(2):895-903.
32. Mugavero MJ, Lin HY, Allison JJ, et al. Racial disparities in HIV virologic failure: Do missed visits matter J Acquir Immune Defic Syndr. 2009;50(1):100-108. doi: 110.1097/QAI.1090b1013e31818d31815c31837
33. WardBA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
34. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6-6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV1 patients treated with standard efavirenzcontaining regimens. Biochem Biophys Res Commun. 2004;319(4):1322-1326.
35. Purcet S, Minuesa G, MolinaArcas M, et al. 30 Azido20,30 dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. Antivir Ther. 2006;11(6):803-811.
36. Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the Pglycoprotein substrate rhodamine 123 from CD56 natural killer cells. Pharmacogenetics. 2001;11(4):293-298.
37. Soares MA, Brindeiro RM, Tanuri A. Primary HIV1 drug resistance in Brazil. AIDS. 2004;18(Suppl 3):S9-S13.
38. Brasil, Ministério da Saúde. Secretária de Vigilância em Saúde. Programa Nacional de DST e Aids. 2008. Recomendações para Terapia Antiretroviral em Adultos Infectados pelo HIV: 2008. 7th edition. Brasília: Ministério da Saúde:Ministério da Saúde, Secretaria de Vigilância em Saúde, Programa Nacional de DST e Aids.
39. de Medeiros LB, Lacerda HR, Cavalcanti AMS, de Albuquerque MFPM. Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. Mem Inst Oswaldo Cruz. 2006;101:845-849.